Inventor · disambiguated record
Derrick Ryan Witcher
Also filed as: WITCHER DERRICK · WITCHER DERRICK R · WITCHER DERRICK RYAN
20 granted patents·11 pending applications·146 citations·filing 1994–2024
94Inventor score
Top patents by PatentIndex Score
31 records- 0196US9290570B2Pan-ELR+ CXC Chemokine AntibodiesLILLY CO ELI·Filed 2014·Granted Mar 22, 2016·20 cites·12 claims
- 0291US10858425B2Pan-ELR+ CXC chemokine antibodiesLILLY CO ELI·Filed 2018·Granted Dec 8, 2020·3 cites·6 claims
- 0391US10093727B2Pan-ELR+ CXC chemokine antibodiesLILLY CO ELI·Filed 2017·Granted Oct 9, 2018·5 cites·10 claims
- 0491US9783605B2Pan-ELR+ CXC chemokine antibodiesLILLY CO ELI·Filed 2016·Granted Oct 10, 2017·5 cites·10 claims
- 0589US8183346B2Anti-ferroportin 1 monoclonal antibodies and uses thereofLEUNG DONMIENNE DOEN MUN·Filed 2009·Granted May 22, 2012·17 cites·7 claims
- 0689US7820163B2Anti-hepcidin antibodies and uses thereofLILLY CO ELI·Filed 2008·Granted Oct 26, 2010·11 cites·9 claims
- 0784US8609817B2Anti-hepcidin-25 selective antibodies and uses thereofLEUNG DONMIENNE DOEN MUN·Filed 2009·Granted Dec 17, 2013·9 cites·17 claims
- 0884US6399859B1Plant uridine diphosphate-glucose dehydrogenase genes, proteins, and uses thereofPIONEER HI BRED INT·Filed 1997·Granted Jun 4, 2002·51 cites·11 claims
- 0981US7479271B2Humanized anti-ghrelin antibodiesLILLY CO ELI·Filed 2006·Granted Jan 20, 2009·4 cites·12 claims
- 1079US12037387B2PAN-ELR+ CXC chemokine antibodies for the treatment of hidradenitis suppurativaLILLY CO ELI·Filed 2019·Granted Jul 16, 2024·1 cites·22 claims
- 1178US6835814B1Protease resistant flint analogsLILLY CO ELI·Filed 2000·Granted Dec 28, 2004·5 cites·6 claims
- 1277US8679497B2Anti-ferroportin 1 monoclonal antibodies and uses thereofLEUNG DONMIENNE DOEN MUN·Filed 2012·Granted Mar 25, 2014·2 cites·20 claims
- 1376US7901679B2Humanized anti-ghrelin antibodiesLILLY CO ELI·Filed 2007·Granted Mar 8, 2011·4 cites·4 claims
- 1476US2024425577A1Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativaLILLY CO ELI·Filed 2024·Application pending·0 cites
- 1575US8765129B2Anti-hepcidin antibodies and uses thereofLILLY CO ELI·Filed 2012·Granted Jul 1, 2014·2 cites·5 claims
- 1674US8329174B2Anti-hepcidin antibodies and uses thereofLEUNG DONMIENNE DOEN MUN·Filed 2010·Granted Dec 11, 2012·2 cites·9 claims
- 1773US9416182B2Anti-TNF-anti-IL-17 bispecific antibodiesLILLY CO ELI·Filed 2014·Granted Aug 16, 2016·2 cites·6 claims
- 1867US6965012B1Flint polypeptide analogsLILLY CO ELI·Filed 2000·Granted Nov 15, 2005·2 cites·6 claims
- 1962US11319370B2CD200R agonist antibodies and uses thereofLILLY CO ELI·Filed 2019·Granted May 3, 2022·0 cites·14 claims
- 2059US2022251198A1Cd200r agonist antibodies and uses thereofLILLY CO ELI·Filed 2022·Application pending·0 cites
- 2154US2007100133A1Erythropoietic compoundsBEALS JOHN M·Filed 2006·Application pending·0 cites
- 2251US2006233788A1Anti-ghrelin antibodiesHEIMAN MARK L·Filed 2004·Application pending·0 cites
- 2350US2022396619A1Cd200 receptor antagonist binding moleculesLILLY CO ELI·Filed 2020·Application pending·0 cites
- 2448US2023159630A1Pan-elr+ cxc chemokine antibodies for the treatment of respiratory diseaseLILLY CO ELI·Filed 2021·Application pending·0 cites
- 2546US2003055221A1Stability of flint through o-linked glycosylationFiled 2000·Application pending·0 cites
- 2645US9951146B2Anti-CD20− / anti-BAFF bispecific antibodiesLILLY CO ELI·Filed 2016·Granted Apr 24, 2018·0 cites·2 claims
- 2743US2005070692A1Anti-interleukin-1 beta analogsFiled 2003·Application pending·0 cites
- 2842US2009060920A1Desacyl ghrelin antibodies and therapeutic uses thereofLILLY CO ELI·Filed 2005·Application pending·0 cites
- 2941US2007237775A1Anti-Ghrelin AntibodiesLILLY CO ELI·Filed 2005·Application pending·0 cites
- 3038US2003100502A1Treating musculoskeletal disorders using lp85 and analogs thereofFiled 2001·Application pending·0 cites
- 3126US5492839AImmunogenic ryanodine derivative and related usesUNIV IOWA RES FOUND·Filed 1994·Granted Feb 20, 1996·1 cites·9 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →